{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "1,1',1''-Phosphoryltriaziridine : Questions médicales les plus fréquentes",
"headline": "1,1',1''-Phosphoryltriaziridine : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les 1,1',1''-Phosphoryltriaziridine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-09",
"dateModified": "2025-04-05",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "1,1',1''-Phosphoryltriaziridine"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Aziridines",
"url": "https://questionsmedicales.fr/mesh/D001388",
"about": {
"@type": "MedicalCondition",
"name": "Aziridines",
"code": {
"@type": "MedicalCode",
"code": "D001388",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.383.097.217"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Thiotépa",
"alternateName": "Thiotepa",
"url": "https://questionsmedicales.fr/mesh/D013852",
"about": {
"@type": "MedicalCondition",
"name": "Thiotépa",
"code": {
"@type": "MedicalCode",
"code": "D013852",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.383.097.217.935.960"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "1,1',1''-Phosphoryltriaziridine",
"alternateName": "Triethylenephosphoramide",
"code": {
"@type": "MedicalCode",
"code": "D013721",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Liusheng Huang",
"url": "https://questionsmedicales.fr/author/Liusheng%20Huang",
"affiliation": {
"@type": "Organization",
"name": "Drug Research Unit, Department of Clinical Pharmacy, University of California San Francisco, USA."
}
},
{
"@type": "Person",
"name": "Beth Apsel Winger",
"url": "https://questionsmedicales.fr/author/Beth%20Apsel%20Winger",
"affiliation": {
"@type": "Organization",
"name": "Department of Pediatrics, University of California San Francisco."
}
},
{
"@type": "Person",
"name": "Vincent Cheah",
"url": "https://questionsmedicales.fr/author/Vincent%20Cheah",
"affiliation": {
"@type": "Organization",
"name": "Drug Research Unit, Department of Clinical Pharmacy, University of California San Francisco, USA."
}
},
{
"@type": "Person",
"name": "David Gingrich",
"url": "https://questionsmedicales.fr/author/David%20Gingrich",
"affiliation": {
"@type": "Organization",
"name": "Drug Research Unit, Department of Clinical Pharmacy, University of California San Francisco, USA."
}
},
{
"@type": "Person",
"name": "Florence Marzan",
"url": "https://questionsmedicales.fr/author/Florence%20Marzan",
"affiliation": {
"@type": "Organization",
"name": "Drug Research Unit, Department of Clinical Pharmacy, University of California San Francisco, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Transition of young adults with metabolic bone diseases to adult care.",
"datePublished": "2023-03-17",
"url": "https://questionsmedicales.fr/article/37008909",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fendo.2023.1137976"
}
},
{
"@type": "ScholarlyArticle",
"name": "Dietary Saturated Fat and Bone Health in Young Adults: The Young Finns Cohort.",
"datePublished": "2022-07-27",
"url": "https://questionsmedicales.fr/article/35896727",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00223-022-01008-5"
}
},
{
"@type": "ScholarlyArticle",
"name": "Perceptions of e-cigarettes among Australian adolescents, young adults, and adults.",
"datePublished": "2023-04-24",
"url": "https://questionsmedicales.fr/article/37121085",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.addbeh.2023.107741"
}
},
{
"@type": "ScholarlyArticle",
"name": "Genomic disparities between cancers in adolescent and young adults and in older adults.",
"datePublished": "2022-11-24",
"url": "https://questionsmedicales.fr/article/36433963",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41467-022-34959-2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Perspective-taking and social inferences in adolescents, young adults, and older adults.",
"datePublished": "2023-03-02",
"url": "https://questionsmedicales.fr/article/36862493",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1037/xge0001337"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés hétérocycliques",
"item": "https://questionsmedicales.fr/mesh/D006571"
},
{
"@type": "ListItem",
"position": 3,
"name": "Composés hétéromonocycliques",
"item": "https://questionsmedicales.fr/mesh/D006573"
},
{
"@type": "ListItem",
"position": 4,
"name": "Azirines",
"item": "https://questionsmedicales.fr/mesh/D001389"
},
{
"@type": "ListItem",
"position": 5,
"name": "Aziridines",
"item": "https://questionsmedicales.fr/mesh/D001388"
},
{
"@type": "ListItem",
"position": 6,
"name": "1,1',1''-Phosphoryltriaziridine",
"item": "https://questionsmedicales.fr/mesh/D013721"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : 1,1',1''-Phosphoryltriaziridine - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur 1,1',1''-Phosphoryltriaziridine",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-12",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur 1,1',1''-Phosphoryltriaziridine",
"description": "Comment diagnostiquer une exposition au Triethylenephosphoramide ?\nQuels tests sont utilisés pour évaluer la toxicité ?\nQuels symptômes indiquent une intoxication ?\nY a-t-il des marqueurs biologiques spécifiques ?\nComment évaluer les effets à long terme ?",
"url": "https://questionsmedicales.fr/mesh/D013721?mesh_terms=Young+Adult&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur 1,1',1''-Phosphoryltriaziridine",
"description": "Quels sont les symptômes d'une exposition aiguë ?\nPeut-on avoir des symptômes neurologiques ?\nQuels symptômes digestifs peuvent apparaître ?\nY a-t-il des symptômes cutanés associés ?\nComment les symptômes évoluent-ils dans le temps ?",
"url": "https://questionsmedicales.fr/mesh/D013721?mesh_terms=Young+Adult&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur 1,1',1''-Phosphoryltriaziridine",
"description": "Comment prévenir l'exposition au Triethylenephosphoramide ?\nQuelles formations sont nécessaires pour les travailleurs ?\nQuels sont les protocoles de sécurité recommandés ?\nComment gérer les déchets contenant ce composé ?\nY a-t-il des recommandations pour les laboratoires ?",
"url": "https://questionsmedicales.fr/mesh/D013721?mesh_terms=Young+Adult&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur 1,1',1''-Phosphoryltriaziridine",
"description": "Quel est le traitement principal en cas d'intoxication ?\nDes antidotes existent-ils pour ce composé ?\nComment traiter les symptômes neurologiques ?\nQuelles mesures de soutien sont recommandées ?\nY a-t-il des traitements spécifiques pour les effets chroniques ?",
"url": "https://questionsmedicales.fr/mesh/D013721?mesh_terms=Young+Adult&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur 1,1',1''-Phosphoryltriaziridine",
"description": "Quelles complications peuvent survenir après exposition ?\nY a-t-il des risques de cancer associés ?\nComment les complications sont-elles surveillées ?\nLes complications peuvent-elles être réversibles ?\nQuels sont les effets à long terme possibles ?",
"url": "https://questionsmedicales.fr/mesh/D013721?mesh_terms=Young+Adult&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur 1,1',1''-Phosphoryltriaziridine",
"description": "Qui est le plus à risque d'exposition ?\nQuels environnements augmentent le risque ?\nY a-t-il des facteurs génétiques impliqués ?\nComment l'âge influence-t-il le risque ?\nLes antécédents médicaux jouent-ils un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D013721?mesh_terms=Young+Adult&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une exposition au Triethylenephosphoramide ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'historique d'exposition et des tests biologiques spécifiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer la toxicité ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins et des analyses d'urine peuvent détecter des métabolites toxiques."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une intoxication ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des nausées, des vomissements et des troubles neurologiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des marqueurs biologiques spécifiques ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des marqueurs comme les enzymes hépatiques peuvent indiquer une toxicité."
}
},
{
"@type": "Question",
"name": "Comment évaluer les effets à long terme ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des suivis réguliers et des évaluations cliniques sont nécessaires pour détecter des effets chroniques."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une exposition aiguë ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes aigus incluent des maux de tête, des vertiges et des troubles respiratoires."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des symptômes neurologiques ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes neurologiques comme des convulsions peuvent survenir."
}
},
{
"@type": "Question",
"name": "Quels symptômes digestifs peuvent apparaître ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des nausées, vomissements et diarrhées sont fréquents après exposition."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes cutanés associés ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées et des irritations peuvent se manifester après contact."
}
},
{
"@type": "Question",
"name": "Comment les symptômes évoluent-ils dans le temps ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent s'aggraver avec le temps si l'exposition se poursuit."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'exposition au Triethylenephosphoramide ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Utiliser des équipements de protection individuelle et suivre les protocoles de sécurité."
}
},
{
"@type": "Question",
"name": "Quelles formations sont nécessaires pour les travailleurs ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des formations sur la manipulation sécurisée des produits chimiques sont essentielles."
}
},
{
"@type": "Question",
"name": "Quels sont les protocoles de sécurité recommandés ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les protocoles incluent des procédures d'urgence et des contrôles d'exposition réguliers."
}
},
{
"@type": "Question",
"name": "Comment gérer les déchets contenant ce composé ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les déchets doivent être éliminés selon les réglementations en vigueur pour les produits toxiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des recommandations pour les laboratoires ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les laboratoires doivent avoir des systèmes de ventilation et des douches de sécurité."
}
},
{
"@type": "Question",
"name": "Quel est le traitement principal en cas d'intoxication ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement principal est l'élimination de l'exposition et le soutien symptomatique."
}
},
{
"@type": "Question",
"name": "Des antidotes existent-ils pour ce composé ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas d'antidote spécifique, le traitement est symptomatique."
}
},
{
"@type": "Question",
"name": "Comment traiter les symptômes neurologiques ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes neurologiques peuvent nécessiter des médicaments anticonvulsivants."
}
},
{
"@type": "Question",
"name": "Quelles mesures de soutien sont recommandées ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des soins de soutien, comme l'hydratation et le monitoring, sont essentiels."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements spécifiques pour les effets chroniques ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements des effets chroniques incluent la réhabilitation et le suivi médical."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir après exposition ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des troubles hépatiques, rénaux et neurologiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de cancer associés ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une exposition prolongée peut augmenter le risque de certains cancers."
}
},
{
"@type": "Question",
"name": "Comment les complications sont-elles surveillées ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des examens médicaux réguliers et des tests de fonction organique sont nécessaires."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement précoce."
}
},
{
"@type": "Question",
"name": "Quels sont les effets à long terme possibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets à long terme peuvent inclure des troubles chroniques et des déficits fonctionnels."
}
},
{
"@type": "Question",
"name": "Qui est le plus à risque d'exposition ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les travailleurs dans l'industrie chimique et les laboratoires sont les plus à risque."
}
},
{
"@type": "Question",
"name": "Quels environnements augmentent le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les environnements de travail mal ventilés et non sécurisés augmentent le risque."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs génétiques impliqués ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des facteurs génétiques peuvent influencer la susceptibilité à la toxicité."
}
},
{
"@type": "Question",
"name": "Comment l'âge influence-t-il le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes âgées peuvent être plus vulnérables aux effets toxiques."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux jouent-ils un rôle ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de maladies hépatiques ou rénales augmentent le risque."
}
}
]
}
]
}
As more accurate diagnostic tools and targeted therapies become increasingly available for pediatric metabolic bone diseases, affected children have a better prognosis and significantly longer lifespa...
Previous studies suggest that saturated fat (SFA) intake may negatively impact on bone. However, few human studies on the topic exist. Women and men aged 31-46 years from the Cardiovascular Risk in Yo...
Increases in e-cigarette use are of concern to public health authorities given the harms associated with vaping. Understanding people's perceptions of the risks and benefits of e-cigarette use has the...
Cancers cause significant mortality and morbidity in adolescents and young adults (AYAs), but their biological underpinnings are incompletely understood. Here, we analyze clinical and genomic disparit...
Taking another person's perspective provides a means to infer their beliefs and intentions (known as Theory of Mind), which is an essential part of social interaction. In this article, we examined how...
Adolescents and young adults have health needs that are distinctly different from children and adults. A lack of education and training is reported by clinicians to be one of the main barriers to prov...
This study documents the current provision of care to young people on an adult inpatient medical ward at a large tertiary teaching hospital in Auckland....
Forty-three staff and 40 patients aged 16-24 years on an adult medical ward completed surveys, which were based on the Northern Regional Alliance, Northern Regional Youth Health Network Standards for ...
Few (12%) staff had completed any specific training in looking after adolescent and young adult patients. Confidentiality was not routinely discussed with young people by 50% of clinicians, and only 2...
Key components of comprehensive developmentally appropriate healthcare were not regularly carried out by staff on an adult medical ward. These findings suggest that further education and training, and...
Opposing theories posited that young adult substance use during the COVID-19 pandemic would decline due to restricted access and social engagement or increase due to efforts to cope with rising distre...
Many studies have shown that "action" videogames (VG) training can improve various cognitive aspects (such as attention, enumeration skill, problem solving, vigilance, inhibitory control and decision ...
Kidney tubules are responsible for the preservation of fluid, electrolyte and acid-base homeostasis via passive and active mechanisms. These physiological processes can be disrupted by inherited or ac...
That no study has investigated oral health-related quality of life (OHRQoL) through the transition from adolescence to young adulthood is partly due to no OHRQoL index having been validated in both ad...
A cross-sectional study was undertaken of a convenience sample of 968 young New Zealand adults aged 18-30 years (83.1% female) using RedCap. Two separate measures of OHRQoL were used (the CPQ...
Internal consistency reliability was high for the CPQ...
The CPQ...